NXL

EFFECT - Nexalin Technology, Inc. (0001527352) (Filer)

S-1/A - Nexalin Technology, Inc. (0001527352) (Filer)

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received written confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq confirmed that the closing bid price of the Company’s common stock was above the $1.00 per share minimum for 21 consecutive trading days, from August 31 through September 29, 2026, following the Company’s previously announced reverse stock split. The confirmation, dated

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The markets are charging into October with a wave of fresh milestones and potential catalysts, putting Nexalin Technology (NASDAQ:NXL), Kraig Biocraft Laboratories (OTCQB:KBLB), Veea (NASDAQ:VEEA), and DataMeds AI (NASDAQ:MEDS) firmly in the market spotlight. Nexalin Technology Targets South America with 10-Year Commercial Push Nexalin Technology (NASDAQ:NXL) has turned what was previously a Brazil-focused commercialization effort into a much broader South American expansion story. On October 1, the company announced a definitive exclusive distribution and local-manufacturing agreement with Inovanexa Medical Technologies cov

Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers Agreement establishes a 10-year commercial framework covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, anchored by an initial 100-device commercialization program and minimum revenue thresholds payable to Nexalin to maintain exclusivity Binding initial purchase order at signing and a clinical pilot targeted within 90 days, supporting a distributor-funded manufacturing fram

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

S-8 - Nexalin Technology, Inc. (0001527352) (Filer)

S-1 - Nexalin Technology, Inc. (0001527352) (Filer)

Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patients  One half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with domain-level gains in comprehension, memory and language function still evident three months after treatment ended. The largest individual gains were observed among patients with the greatest cognitive impairment at baseline. Findings are expected to directly inform endpoint sel

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on August 28, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Marke

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

424B5 - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

10-Q - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

DEF 14A - Nexalin Technology, Inc. (0001527352) (Filer)

PRE 14A - Nexalin Technology, Inc. (0001527352) (Filer)

Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil Award-winning research evaluated Nexalin’s DIFS™ 15 mA, 77.5 Hz platform for insomnia symptoms in patients with comorbid anxiety, with the primary reported finding being a significant, durable improvement in sleep quality Independent scientific recognition further strengthens the growing clinical and scientific visibility behind Nexalin’s differentiated, non-invasive frequency-based neurostimulation platform as the Company prepares for product launch in Brazi